Witnessing the stock’s movement on the chart, on Wednesday, Akero Therapeutics Inc (NASDAQ: AKRO) set off with pace as it heaved 0.55% to $30.92, before settling in for the price of $30.75 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $15.32-$37.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 1.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -34.94%. This publicly-traded company’s shares outstanding now amounts to $69.61 million, simultaneously with a float of $58.43 million. The organization now has a market capitalization sitting at $2.16 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.51, while the 200-day Moving Average is $25.78.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 16.29%, in contrast to 92.02% institutional ownership. According to the most recent insider trade that took place on Dec 02 ’24, this organization’s President and CEO sold 25,000 shares at the rate of 32.09, making the entire transaction reach 802,250 in total value, affecting insider ownership by 605,417. Preceding that transaction, on Dec 02 ’24, Company’s Chief Operating Officer sold 10,000 for 32.13, making the whole transaction’s value amount to 321,310. This particular insider is now the holder of 206,286 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Akero Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -34.94% and is forecasted to reach -4.74 in the upcoming year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 17.25. The Stock has managed to achieve an average true range (ATR) of 1.56.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.75, a figure that is expected to reach -1.16 in the next quarter, and analysts are predicting that it will be -4.74 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Going through the that latest performance of [Akero Therapeutics Inc, AKRO]. Its last 5-days volume of 0.58 million was inferior to the volume of 0.86 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 41.12% While, its Average True Range was 1.49.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 61.99%, which indicates a major rise in contrast to 61.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 54.67% that was higher than 48.38% volatility it exhibited in the past 100-days period.
